Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Tenax Therapeutics Inc (TENX) USD0.0001

Sell:$1.25 Buy:$1.66 Change: $0.05 (3.94%)
NASDAQ:0.77%
Market closed |  Prices as at close on 27 May 2020 | Switch to live prices |
Sell:$1.25
Buy:$1.66
Change: $0.05 (3.94%)
Market closed |  Prices as at close on 27 May 2020 | Switch to live prices |
Sell:$1.25
Buy:$1.66
Change: $0.05 (3.94%)
Market closed |  Prices as at close on 27 May 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Contact details

Address:
1 Copley Pkwy Ste 490
MORRISVILLE
27560-9693
United States
Telephone:
+1 (919) 8064414
Website:
www.tenaxthera.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TENX
ISIN:
US88032L2097
Market cap:
$10.88 million
Shares in issue:
9.22 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ronald Blanck
    Independent Chairman of the Board
  • Michael Jebsen
    President, Chief Financial Officer
  • Anthony DiTonno
    Chief Executive Officer, Director
  • Douglas Hay
    Executive Vice President - Regulatory Affairs
  • Doug Randall
    Executive Vice President - Business and Commercial Operations
  • Paula Bokesch
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.